These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27385318)

  • 1. Identification of matrix metalloproteinase-12 as a candidate molecule for prevention and treatment of cardiometabolic disease.
    Amor M; Moreno Viedma V; Sarabi A; Grün NG; Itariu B; Leitner L; Steiner I; Bilban M; Kodama K; Butte AJ; Staffler G; Zeyda M; Stulnig TM
    Mol Med; 2016 Oct; 22():487-496. PubMed ID: 27385318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common dysregulated pathways in obese adipose tissue and atherosclerosis.
    Moreno-Viedma V; Amor M; Sarabi A; Bilban M; Staffler G; Zeyda M; Stulnig TM
    Cardiovasc Diabetol; 2016 Aug; 15(1):120. PubMed ID: 27561966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes.
    Bonen A; Tandon NN; Glatz JF; Luiken JJ; Heigenhauser GJ
    Int J Obes (Lond); 2006 Jun; 30(6):877-83. PubMed ID: 16418758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation].
    Vanuzzo D; Pilotto L; Mirolo R; Pirelli S
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):6S-17S. PubMed ID: 18773746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visceral adipose tissue indicates the severity of cardiometabolic risk in patients with and without type 2 diabetes: results from the INSPIRE ME IAA study.
    Smith JD; Borel AL; Nazare JA; Haffner SM; Balkau B; Ross R; Massien C; Alméras N; Després JP
    J Clin Endocrinol Metab; 2012 May; 97(5):1517-25. PubMed ID: 22337910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
    Pereira CD; Azevedo I; Monteiro R; Martins MJ
    Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of early cardiometabolic risk factors in children and adolescents with Turner syndrome.
    O'Gorman CS; Syme C; Lang J; Bradley TJ; Wells GD; Hamilton JK
    Clin Endocrinol (Oxf); 2013 Jun; 78(6):907-13. PubMed ID: 23106295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cell membrane glycoprotein 1 (PC-1): a marker of insulin resistance in obesity, uremia and diabetes mellitus.
    Stefanović V; Antić S
    Clin Lab; 2004; 50(5-6):271-8. PubMed ID: 15209435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary).
    ; Leiter LA; Fitchett DH; Gilbert RE; Gupta M; Mancini GB; McFarlane PA; Ross R; Teoh H; Verma S; Anand S; Camelon K; Chow CM; Cox JL; Després JP; Genest J; Harris SB; Lau DC; Lewanczuk R; Liu PP; Lonn EM; McPherson R; Poirier P; Qaadri S; Rabasa-Lhoret R; Rabkin SW; Sharma AM; Steele AW; Stone JA; Tardif JC; Tobe S; Ur E
    Can J Cardiol; 2011; 27(2):124-31. PubMed ID: 21459258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group.
    ; Leiter LA; Fitchett DH; Gilbert RE; Gupta M; Mancini GB; McFarlane PA; Ross R; Teoh H; Verma S; Anand S; Camelon K; Chow CM; Cox JL; Després JP; Genest J; Harris SB; Lau DC; Lewanczuk R; Liu PP; Lonn EM; McPherson R; Poirier P; Qaadri S; Rabasa-Lhoret R; Rabkin SW; Sharma AM; Steele AW; Stone JA; Tardif JC; Tobe S; Ur E
    Can J Cardiol; 2011; 27(2):e1-e33. PubMed ID: 21459257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone and the metabolic syndrome.
    Johannsson G; Bengtsson BA
    J Endocrinol Invest; 1999; 22(5 Suppl):41-6. PubMed ID: 10442570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of plasma metabolite profiles related to adipose tissue distribution and cardiometabolic risk.
    Boulet MM; Chevrier G; Grenier-Larouche T; Pelletier M; Nadeau M; Scarpa J; Prehn C; Marette A; Adamski J; Tchernof A
    Am J Physiol Endocrinol Metab; 2015 Oct; 309(8):E736-46. PubMed ID: 26306599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The metabolic syndrome. Part II: its mechanisms of development and its complications].
    Pacholczyk M; Ferenc T; Kowalski J
    Postepy Hig Med Dosw (Online); 2008 Oct; 62():543-58. PubMed ID: 18936730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial.
    Vlassara H; Cai W; Tripp E; Pyzik R; Yee K; Goldberg L; Tansman L; Chen X; Mani V; Fayad ZA; Nadkarni GN; Striker GE; He JC; Uribarri J
    Diabetologia; 2016 Oct; 59(10):2181-92. PubMed ID: 27468708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Components of the metabolic syndrome among a sample of overweight and obese Costa Rican schoolchildren.
    Holst-Schumacher I; Nuñez-Rivas H; Monge-Rojas R; Barrantes-Santamaría M
    Food Nutr Bull; 2009 Jun; 30(2):161-70. PubMed ID: 19689095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of high-fat diet-induced adipose tissue remodeling in obese diabetic mice by n-3 polyunsaturated fatty acids.
    Huber J; Löffler M; Bilban M; Reimers M; Kadl A; Todoric J; Zeyda M; Geyeregger R; Schreiner M; Weichhart T; Leitinger N; Waldhäusl W; Stulnig TM
    Int J Obes (Lond); 2007 Jun; 31(6):1004-13. PubMed ID: 17130847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Worsening of obesity and metabolic status yields similar molecular adaptations in human subcutaneous and visceral adipose tissue: decreased metabolism and increased immune response.
    Klimcáková E; Roussel B; Márquez-Quiñones A; Kovácová Z; Kováciková M; Combes M; Siklová-Vítková M; Hejnová J; Srámková P; Bouloumié A; Viguerie N; Stich V; Langin D
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E73-82. PubMed ID: 21047918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.